Replies to post #546440 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The combo patent does exist.

It is a use patent that would read on anybody using both a certain type of DC vaccine and a CI in brain cancers

When first submitted, they tried for basically any combo of immuno therapies. The PTO kept rejecting that as obvious based on the numerous trials already doing so. So they slowly whittled it down to what is left.

I do think they can get the patent issued. As far as value, it has little for several reasons.

First, it is fairly specific. Despite assertions that NWBO can broaden it, they already tried to and failed.

Second, nobody is close to any suck combo being on the market. Even Dr T Cloughsey (the trial PI) says the present trial is not designed to establish efficacy. So when that trial completes and has data in 2026 or so somebody will have to decide if they want to run a P3. And then wait.

Third, it is assigned to 3 different companies. That means if Joe's DC wants to infringe by using their product with a CI, they can go to Revimune or CRL and get a license. All assignees have a right to use, or license, the patent.

[SkyLimit2022]

Thanks for your views.

I’m not a patent attorney, and certainly not an expert in international patent law, but I believe they have brilliantly covered the entire drug class commonly referred to as PD-1 inhibitors. If I recall, the Israeli patent naming Northwest Biotherapeutics covered the combo with checkpoint inhibitors.

The company has built a comprehensive worldwide patent portfolio. Their actions seem consistently steady and circumspect over time, and they have demonstrated great foresight in my opinion.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

[Red_Right_Hand]

Googling to solve patent 'mystery'
https://patents.google.com/patent/US20150273033A1/